Coagulation

Standardising anticoagulant dosing via D-Dimer: experiences from a Chinese hospital

Standardising anticoagulant dosing via D-Dimer: experiences from a Chinese hospital

Despite the availability of new anticoagulant drugs, direct oral anticoagulants like warfarin and heparin remain the most used in the world. Anticoagulation drug dosing and management are critical for the prevention, treatment and reduction of thrombotic episodes in patients. However, clinical use still varies from practice to practice. In the hopes of providing standardisation, Professor

Standardising anticoagulant dosing via D-Dimer: experiences from a Chinese hospital Read More »

Coagulation disorders in heart failure: pathophysiology and clinical management

Coagulation disorders in heart failure: pathophysiology and clinical management

Heart failure (HF) is a clinical syndrome caused by a structural or functional disorder of the heart that results in elevated intracardiac pressures and/or inadequate cardiac output during exercise or rest. The condition is associated with an increased risk of both arterial and venous thrombotic events. Greater awareness of the issue among clinicians, as well

Coagulation disorders in heart failure: pathophysiology and clinical management Read More »

VTE associated with hormone therapy and pregnancy: Assoc Prof Lai Heng Lee on risk and management

VTE associated with hormone therapy and pregnancy - Assoc Prof Lai Heng Lee on risk and management_thumbnail

At the annual Roche Diagnostics-sponsored event pro-COAG event (2022), Prof Lai Heng Lee gave an insightful presentation on the risk management of venous thromboembolism (VTE) associated with hormone therapy and pregnancy. Below are some key takeaways. Hormone-associated venous thromboembolism (VTE) The incidence of VTE in young women is generally 1/10,000 per year. However, hormonal therapy

VTE associated with hormone therapy and pregnancy: Assoc Prof Lai Heng Lee on risk and management Read More »

How haemophilia diagnostics and treatments help drive ‘Access for All’

joyce thumb 2

April 17th is World Haemophilia Day, an international campaign designed to honour the people and families coping with this rare condition and raise awareness of the disease. This year’s campaign focuses on “Access for All: Prevention of bleeds as the global standard of care” and ensuring that treatments are available globally. Clinical lab diagnostics can

How haemophilia diagnostics and treatments help drive ‘Access for All’ Read More »

Venous thromboembolism (VTE) in Asia: risk factors, diagnosis and treatment

Venous thromboembolism (VTE) in Asia: risk factors, diagnosis and treatment

Both Western and Asian populations have similar risk factors for venous thromboembolism (VTE), a condition that typically manifests as deep vein thrombosis (DVT) or pulmonary embolism (PE). Yet evidence suggests that VTE cases in Asia may be significantly underreported [1]. Since VTE is a major problem for patients and healthcare systems, this reporting gap needs

Venous thromboembolism (VTE) in Asia: risk factors, diagnosis and treatment Read More »

Venous thromboembolism (VTE) in women: incidence, risk factors and treatment

Venous thromboembolism (VTE) in women: incidence, risk factors and treatment

Venous thromboembolism (VTE) refers to blood clots that develop in the veins [1]. The two most common manifestations of VTE are deep vein thrombosis (DVT) and pulmonary embolism (PE) [1]. DVT is when a blood clot develops in a deep vein, and PE occurs when a clot breaks loose, travels through the bloodstream, and lodges

Venous thromboembolism (VTE) in women: incidence, risk factors and treatment Read More »

Biomarkers in cancer-associated thrombosis: insights from Prof Anna Falanga and Cinzia Giaccherini

Biomarkers in cancer-associated thrombosis: insights from Prof Anna Falanga and Cinzia Giaccherini

In a webinar that was held World Thrombosis Day 2022, two coagulation experts—Prof Anna Falanga, Professor of Hematology at University of Milan Bicocca, and Cinzia Giaccherini, a research biologist with more than 10 years of experience in hemostasis and thrombosis—discussed the predictive role of biomarkers in cancer-associated thrombosis (CAT). Prof Anna Falanga began by presenting

Biomarkers in cancer-associated thrombosis: insights from Prof Anna Falanga and Cinzia Giaccherini Read More »

Thrombosis risk and anticoagulation in hospitalised patients: insights from Prof Alex C Spyropoulos

Thrombosis risk and anticoagulation in hospitalised patients: insights from Prof Alex C Spyropoulos

At pro-COAG, an annual scientific and educational event on coagulation sponsored by Roche Diagnostics that was last held in Mar 2022, Prof Alex C Spyropoulos, a Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell and Director of Anticoagulation and Clinical Thrombosis Services for the multi-hospital Northwell Health System in New York, spoke

Thrombosis risk and anticoagulation in hospitalised patients: insights from Prof Alex C Spyropoulos Read More »

Thrombosis in cancer and inflammation: insights from Prof Ng Heng Joo

Thrombosis in cancer and inflammation: insights from Prof Ng Heng Joo

At pro-COAG, an annual scientific and educational event on coagulation sponsored by Roche Diagnostics that was last held in Mar 2022, Prof Ng Heng Joo, Head and Senior Consultant at the Department of Haematology at Singapore General Hospital in Singapore, reviewed the causation, development and treatment of venous thrombotic events in cancer and inflammation. Cancer

Thrombosis in cancer and inflammation: insights from Prof Ng Heng Joo Read More »

Scroll to Top